» Articles » PMID: 22961644

Recurrent Non-small Cell Lung Cancer: Evaluation of CT-guided Radiofrequency Ablation As Salvage Therapy

Overview
Journal Acta Radiol
Specialty Radiology
Date 2012 Sep 11
PMID 22961644
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Radiofrequency ablation (RFA) is a potential application as a salvage tool after failure of surgery, chemotherapy, or radiotherapy of non-small cell lung cancer (NSCLC). Although several studies have evaluated the use of RFA in primary NSCLC, there is little literature on its potential application as a salvage tool.

Purpose: To evaluate CT-guided RFA employed as a salvage therapy for pulmonary recurrences of NSCLC after prior treatment with chemotherapy, radiation therapy, and/or surgery.

Material And Methods: A retrospective computer database search yielded 33 patients with biopsy proven primary NSCLC who underwent CT-guided RFA of 39 recurrent tumors following surgery, chemotherapy, and/or radiotherapy. Follow-up imaging was performed with CT and PET-CT. The endpoints of interest were progression-free survival (PFS) and time to local progression (TTLP). PFS and TTLP were compared by lesion size (<3 cm, ≥3 cm).

Results: The median PFS was 8 months. For patients with a tumor size <3 cm median PFS was 11 months, whereas the median PFS of patients with a tumor size ≥3 cm was 5 months. The difference did not reach statistical significance (P = 0.09). The median TTLP of all tumors was 14 months. TTLP of ablated tumors <3 cm in size was 24 months, compared to 8 months for ablated tumors ≥3 cm in size. The difference did not reach statistical significance (P = 0.07).

Conclusion: RFA of recurrent NSCLC may be a valuable salvage tool to achieve local tumor control, especially in tumors measuring <3 cm in size.

Citing Articles

Combination of Local Ablative Techniques with Radiotherapy for Primary and Recurrent Lung Cancer: A Systematic Review.

Bonome P, Pezzulla D, Lancellotta V, Scrofani A, Macchia G, Rodolfino E Cancers (Basel). 2023; 15(24).

PMID: 38136413 PMC: 10741973. DOI: 10.3390/cancers15245869.


Radiofrequency ablation for stage <IIB non-small cell lung cancer: Opportunities, challenges, and the road ahead.

Zhao Q, Wang J, Fu Y, Hu B Thorac Cancer. 2023; 14(32):3181-3190.

PMID: 37740563 PMC: 10643797. DOI: 10.1111/1759-7714.15114.


[Current Treatment Status and Prospect of Surgery and Thermal Ablation for 
Pulmonary Oligometastases in Non-small Cell Lung Cancer].

Liu B Zhongguo Fei Ai Za Zhi. 2023; 26(3):238-244.

PMID: 37035886 PMC: 10106791. DOI: 10.3779/j.issn.1009-3419.2023.106.06.


Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy.

Ghosn M, Solomon S Cancers (Basel). 2021; 13(20).

PMID: 34680348 PMC: 8534236. DOI: 10.3390/cancers13205202.


Salvage surgery for local recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: a systematic review.

Dickhoff C, Rodriguez Schaap P, Otten R, Heymans M, Heineman D, Dahele M Ther Adv Med Oncol. 2018; 10:1758835918787989.

PMID: 30023008 PMC: 6047243. DOI: 10.1177/1758835918787989.